Organovo to Present at 30th Annual ROTH Conference
March 08 2018 - 7:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced
that Chief Financial Officer Craig Kussman is scheduled to speak at
the 30th Annual ROTH Conference in Dana Point, Ca., on Monday,
March 12th at 7:30 a.m. Pacific Time (PT). The presentation will be
simultaneously audio webcast at http://www.organovo.com. The audio
webcast will be archived for 90 days following the conference.
About Organovo Holdings, Inc.Organovo is
developing and commercializing a platform technology to produce and
study living tissues that emulate key aspects of human biology and
disease for use in drug discovery, clinical development, and
therapeutic applications. The Company develops tissue systems
through internal research programs and in collaboration with
pharmaceutical, academic and other partners. Organovo's living
tissues have the potential to transform the drug discovery process,
enabling treatments to be developed more effectively and with
greater relevance to performance in human trials and
commercialization. The Company’s ExVive™ Liver and Kidney Tissues
are used in high-value drug profiling, including compound screening
in disease models, toxicology, target and marker
discovery/validation, and other drug testing. The Company is also
advancing a preclinical program to develop its NovoTissues® liver
therapeutic tissues for critical unmet medical needs, including
certain life-threatening pediatric diseases. Organovo is changing
the shape of life science research and transforming medical care.
Learn more at www.organovo.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements regarding the potential for one or more
customer’s electing to move toward framework agreements involving
annual budgets, revenue commitments, and/or dedicated research
plans, the expected costs, timing and operational benefits of the
Company’s restructuring plan, the financial impact of the Company’s
restructuring plan on its future operating costs and financial
results, and statements regarding the potential benefits and
therapeutic uses of the Company’s therapeutic liver tissue. The
factors that could cause the Company's actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products and services based on
its technology; the expected benefits and efficacy of the Company's
products, services and technology; the Company’s ability to
successfully complete studies and provide the technical information
required to support market acceptance of its products, services and
technology, on a timely basis or at all; the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies, including its use of third party
distributors; the Company’s ability to recognize deferred revenue;
the final results of the Company's preclinical studies may be
different from the Company's studies or interim preclinical data
results and may not support further clinical development of its
therapeutic tissues; the Company may not successfully complete the
required preclinical and clinical trials required to obtain
regulatory approval for its therapeutic tissues on a timely basis
or at all; and the Company’s ability to meet its fiscal year 2018
outlook. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including its
Annual Report on Form 10-K filed with the SEC on June 7, 2017. You
should not place undue reliance on these forward-looking
statements, which speak only as of the date that they were made.
These cautionary statements should be considered with any written
or oral forward-looking statements that the Company may issue in
the future. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to reflect actual results, later events or circumstances
or to reflect the occurrence of unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024